Patent settlement unlawfully delayed generic competition for Amitiza.
By Joy M. Sidhwa
When drug makers pay would‑be generic competitors to stay off the market, businesses and consumers absorb the cost in the form of higher prices. It’s often up to the courts to hold companies liable for this kind of behavior.
A federal jury in the U.S. District Court for the District of Massachusetts did just that and returned a verdict against Takeda Pharmaceutical Company in antitrust litigation concerning its branded constipation drug Amitiza® (lubiprostone). The panel awarded plaintiffs $885 million, an amount subject to trebling under federal antitrust law, putting Takeda’s potential exposure in the multi-billion-dollar range.
Damages were awarded to the wholesaler class ($475 million) and individual retailer plaintiffs ($345 million), while damages assessed by the jury to the end‑payor class ($65 million) remain subject to further proceedings.
Takeda will appeal, saying the verdict is not final and that liability has not been fixed pending entry of judgment.
Background of the Takeda Amitiza Case
The verdict follows several weeks of trial in antitrust actions filed beginning in 2021 against three Takeda entities: Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A., Inc., and Takeda Pharmaceuticals America, Inc.
The consolidated action brought together claims by a putative class of wholesalers, a putative class of third‑party payors, and individual retail pharmacies.
Plaintiffs alleged that a 2014 patent settlement between Takeda, its then‑collaboration partner Sucampo Pharmaceuticals, Inc., and Par Pharmaceutical, Inc. unlawfully delayed generic competition for Amitiza.
Takeda has maintained that the settlement resulted from an arm’s‑length negotiation consistent with the Hatch‑Waxman Act, and that it permitted Par to launch an authorized generic on January 1, 2021, more than six years before the expiration of certain Amitiza patents and approximately 17 months before Par’s ANDA approval. Other generic manufacturers subsequently entered pursuant to licensed entry dates.
Takeda’s collaboration and license agreement with Sucampo terminated on March 31, 2024. Takeda no longer sells or markets Amitiza.
What the Jury Was Asked to Decide in the Takeda Case
The case was tried under the analytical framework established by the Supreme Court in FTC v. Actavis, which governs antitrust challenges to so‑called “reverse‑payment” or “pay‑for‑delay” patent settlements.
According to reports, jurors were directed to evaluate the settlement under federal antitrust standards and to determine whether Takeda’s 2014 agreement reflected a lawful resolution of patent litigation or an unlawful agreement involving a transfer of value that delayed generic entry.
Consistent with Actavis, the jury was instructed to assess:
- Whether any value provided to the generic challenger was tied to postponing competition; and
- Whether Takeda’s asserted pro‑competitive justifications, including its arguments regarding patent strength and litigation risk, outweighed any anticompetitive effects.
Jurors were not asked to determine patent validity directly. Instead, they were tasked with evaluating the economic substance of the agreement and its competitive impact under the Rule of Reason, i.e., did the structure and timing of the settlement effectively pay to keep generics off the market and force purchasers to continue paying supracompetitive prices?
Takeda said in a statement that the case lacks merit and that it will seek to reverse the verdict. “We also believe that there were both evidentiary and legal errors made during the trial,” the statement read.
Why the Takeda Verdict Matters
The Takeda Amitiza verdict underscores several themes that continue to shape pharmaceutical antitrust litigation:
Continued Force of Actavis. More than a decade after the Supreme Court’s decision, Actavis remains the governing framework for evaluating reverse‑payment settlements. Where plaintiffs can persuade jurors that a transfer of value lacked legitimate settlement justification and delayed competition, liability exposure can be substantial. This marks the first jury verdict holding pharma companies liable.
Economic Substance Over Form. Modern pay‑for‑delay cases rarely involve straightforward cash payments. Instead, juries are asked to evaluate whether licensing arrangements, supply agreements, or other business terms functioned—economically—as compensation for delayed entry.
Sophisticated Plaintiffs and Damages Proof. The participation of pharmacies, insurers, and other institutional purchasers raises both the stakes and the sophistication of damages models, often supported by extensive econometric analysis of alleged overcharges.
Jury‑Driven Outcomes. As this case illustrates, reverse‑payment disputes increasingly turn on how complex economic and legal theories are presented to and understood by juries.
Bottom Line
Post‑trial motions and /or an appeal are expected to focus on jury instructions, sufficiency of the evidence, and the admissibility of expert testimony. In the meantime, the case adds to a growing body of jury verdicts addressing reverse‑payment settlements under Actavis.
The Takeda Amitiza verdict highlights the enduring tension at the heart of pharmaceutical antitrust law: balancing patent‑based incentives against the competitive benefits of timely generic product entry.
For companies negotiating patent settlements – and their competitors – the message remains consistent. Structure, documentation, and economic justification matter. And in close cases, those decisions may ultimately be judged by a jury.
For competitors, these patent settlements may signal that a rival is reshaping the playing field, warranting antitrust scrutiny. For purchasers, they may indicate overcharges and potential claims.
Contact
Antitrust risk runs up and down the supply chain, not just between a brand and a generic. Should you or your client be operating in a supply chain affected by anticompetitive conduct, attorneys at Mogin Law LLP are available to answer questions and discuss your concerns.
Takeaways for Businesses
Pay‑for‑Delay Risk Is Not Just a “Pharma Company” Problem. The Takeda verdict illustrates that pay‑for‑delay arrangements can affect—and expose—a broad range of market participants, from manufacturers to wholesalers, pharmacies, and insurers. Why it matters: Antitrust risk now runs up and down the supply chain, not just between a brand and a generic.
Competitors Are Not Powerless When Rivals Delay Entry. Companies that compete against firms using pay‑for‑delay tactics—whether branded or generic—may suffer lost sales, delayed entry, or foreclosed opportunities as a result of anticompetitive settlements. Why it matters: Competitors increasingly evaluate whether rival settlements unlawfully distort competitive conditions, not merely whether regulators intervene.
Purchasers Are Proving They Are Willing and Able to Litigate. Wholesalers, pharmacies, insurers, and other institutional purchasers were the driving force behind the Takeda verdict, supported by sophisticated damages models and class structures. Why it matters: Downstream buyers are no longer passive victims of delayed competition; they are active plaintiffs with the resources to try cases to verdict.
“Value” Is Evaluated Economically, Not Formally. Across all perspectives—defendants, competitors, and purchasers—the key question remains whether an agreement functions in practice to delay competition through a transfer of value. Why it matters: What matters is economic substance, not how a transaction is described in a contract or term sheet.
Strong Patents Do Not End the Inquiry. Even where patent strength and litigation risk are genuine, juries may still conclude that a settlement crossed the antitrust line if it postponed competition through unjustified value transfers. Why it matters: Patent rights shape—but do not control—the antitrust analysis.
The Takeda Verdict Reinforces a Single Unifying Lesson. Agreements that shape market entry can create antitrust risk not only for those who negotiate them, but also opportunities—and exposure—for competitors and purchasers affected by their competitive impact. Why it matters: For businesses operating anywhere along the pharmaceutical supply chain, the question is no longer whether pay‑for‑delay scrutiny exists, but how it may intersect with your role in the market.
If you have questions contact us at Info@MoginLawLLP.com.
Members of the press are encouraged to contact us at Media@MoginLawLLP.com.
FAQ
Potential plaintiffs include:
generic or branded competitors harmed by delayed entry, wholesalers and distributors paying supracompetitive prices, pharmacies and pharmacy chains,
insurers and health plans, and in some cases, state attorneys general.
You should contact a qualified competition law firm that has experience with these types of matters. Getting a high-level assessment of whether you have a potentially actionable antitrust case is a good business practice. Contact Mogin Law LLP if you would like to schedule a consultation.
Competitors should monitor:
settlements that foreclose earlier entry opportunities,
side deals that appear economically disconnected from legitimate business needs, and
market outcomes inconsistent with expected competitive dynamics.
Because pay‑for‑delay risk often surfaces in:
IP litigation strategy, licensing and collaboration agreements,
M&A diligence, supply and distribution negotiations, and
long‑term pricing and market‑access planning.